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Abstract
Background. Glioblastoma (GBM) has a 5-year survival rate of 3%-5%. GBM treatment includes maximal resection
followed by radiotherapy with concomitant and adjuvant temozolomide (TMZ). Cytochrome C oxidase (CcO) is a
mitochondrial enzyme involved in the mechanism of resistance to TMZ. In a prior retrospective trial, CcO activity in
GBMs inversely correlated with clinical outcome. The current Cyto-C study was designed to prospectively evaluate
and validate the prognostic value of tumor CcO activity in patients with newly diagnosed primary GBM, and compared to the known prognostic value of MGMT promoter methylation status.
Methods. This multi-institutional, blinded, prospective biomarker study enrolled 152 patients with newly
diagnosed GBM who were to undergo surgical resection and would be candidates for standard of care. The
primary end point was overall survival (OS) time, and the secondary end point was progression-free survival (PFS) time. Tumor CcO activity and MGMT promoter methylation status were assayed in a centralized
laboratory.
Results. OS and PFS did not differ by high or low tumor CcO activity, and the prognostic validity of MGMT promoter methylation was confirmed. Notably, a planned exploratory analysis suggested that the combination of low
CcO activity and MGMT promoter methylation in tumors may be predictive of long-term survival.
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which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

Downloaded from https://academic.oup.com/noa/article/4/1/vdab186/6482703 by Washington University, Law School Library user on 16 December 2022

Prospective biomarker study in newly diagnosed
glioblastoma: Cyto-C clinical trial

2

Griguer et al. Prospective biomarker trial in glioblastoma

Key Points
• The NeuroNext NN106 (Cyto-C) study was the first prospective blinded biomarker
trial conducted in glioblastoma patients, and applied many components of the
prospective-specimen collection, retrospective-blinded evaluation (PRoBE) design.
• The level of CcO had no prognostic value on overall survival or progression-free
survival in glioblastoma.
• The combination of low CcO activity and MGMT promoter methylation status may
be predictive of long-term survival and warrants further study.

Importance of the Study
To the best of our knowledge, we conducted,
the first clinical trial to prospectively evaluate
a prognostic biomarker in primary GBM. The
clinical trial incorporates biomarker-relevant
(non-interventional) elements of a “PRoBE”
design, including blinding. A significant
strength of our study was the diversity of the
study sample (race, sex, age) and geographic
reach (19 sites across the United States).
Multi-institutional biomarker studies that require rapid tissue acquisition and processing,
prior to centralized review, are feasible with

Glioblastoma (GBM) is the most aggressive primary brain
tumor. Even with the current standard of care (SOC) treatment, which includes radiation and concomitant and adjuvant temozolomide (TMZ),1,2 the median survival time for
patients with primary GBM is only 14 months.3 This poor
survival time may be due, in part, to the heterogeneity observed in GBM from different patients and even within primary and recurrent tumors.4,5 This heterogeneity suggests
that unique treatment strategies may be necessary for
subsets of GBMs. Among the many potential biomarkers
assessed in GBM, methylation of the O6-methylguanine
(O6-meG) DNA methyltransferase gene (MGMT) promoter
is a reliable predictor of a favorable clinical response to
TMZ.1 Beyond MGMT promoter methylation status and despite extensive efforts, a molecular signature that can be
used as a prognostic or predictive marker in GBM remains
lacking.6,7 Among the many potential biomarkers assessed
in GBM, methylation of MGMT promoter is a reliable predictor of a favorable clinical response to TMZ.1 Recently, we
also observed that cytochrome C oxidase (CcO, complex
IV; EC 1.9.3.1) activity level associated with the acquisition
of chemoresistance to TMZ in malignant gliomas.8,9

a multidisciplinary team. A high percentage
of patients consented to having their tissue
studied, even prior to surgery and definitive
diagnosis. While the level of CcO was not validated to have prognostic value on overall survival, exploratory analysis showed that low
CcO activity and MGMT promoter methylation in GBMs may be a predictive marker for
longer survival. Additional prospective cohorts
are needed to confirm our findings and determine the utility of this potential combination
of biomarkers.

CcO is the terminal enzyme of the mitochondrial respiratory chain (electron transport chain [ETC]) that catalyzes the transfer of electrons from cytochrome C (Cyt
c) to oxygen (O2), and thus regulates the electron flux
capacity of the ETC. Of particular relevance to GBM
therapy, high CcO activity supports more efficient mitochondrial coupling and thus decreased the production of reactive oxygen species (ROS),8–11 thereby
diminishing the efficacy of chemotherapeutic drugs
such as TMZ.12,13 In our previous retrospective study,
high CcO activity was correlated with poor overall
survival (OS) and progression-free survival (PFS).14
A receiver-operating characteristic (ROC) analysis in
that study determined that a CcO/citrate synthase (CS)
ratio of 4 was the optimal cutoff value. Given that such
a biomarker would allow the identification of subsets of
patients that exhibit similar characteristics, we set out
to confirm the prognostic value of CcO activity status
(high CcO/CS > 4 vs low CcO/CS ≤ 4) in a prospective,
blinded, multicenter trial (the Cyto-C study), and compare its utility as a biomarker with that of MGMT promoter methylation status.
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Conclusions. Tumor CcO activity alone was not confirmed as a prognostic marker in GBM patients. However,
the combination of low CcO activity and methylated MGMT promoter may reveal a subgroup of GBM patients with improved long-term survival that warrants further evaluation. Our work also demonstrates the
importance of performing large, multi-institutional, prospective studies to validate biomarkers. We also discuss lessons learned in assembling such studies.
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Materials and Methods
Trial Organization

Patients, Treatment, and Follow-up
The study consisted of an enrollment phase followed
by a 24-month follow-up phase wherein the primary
endpoint was OS and the secondary endpoint was PFS.
Subjects with a potential diagnosis of a brain tumor
were consented for tissue collection prior to initial surgical resection. Key eligibility criteria included subjects
≥21 years of age, a newly diagnosed GBM centrally
confirmed at the University of Alabama at Birmingham
(UAB), and availability of tumor tissue representative of
GBM following tumor resection. Key exclusion criteria
were secondary GBM or other gliomas, planned upfront
treatment with any anti-angiogenic agent targeting
the vascular endothelial growth factor pathway, or
any immunotherapy regimen. Complete details regarding inclusion and exclusion criteria are provided in
Supplementary file 1. Subjects consented to allow excess brain tumor tissue to be sent for central review,
analysis and to allow study staff to collect information
from their clinical records. Once consent was obtained,
the diagnosis of primary GBM was confirmed by on-site
neuropathologists and centrally confirmed at UAB. All
subjects received maximal safe resection followed by
radiation with concomitant TMZ, then maintenance TMZ
chemotherapy as prescribed by their treating physician.
The SOC follow-up schedule was per each institution’s
typical SOC protocol. While on therapy, subjects were
evaluated in clinic or via telephone interviews at
3-month intervals from the time of surgery. At the end
of 24 months or at the time of death, the site completed
an exit form that specified treatment details and time of
tumor progression. Each subject’s clinical records were
reviewed by study staff who extracted pertinent data for
the study.

Mitochondrial Isolation
Isolation of mitochondria from GBMs was performed as
previously described.14 Briefly, each tumor specimen was
weighed, minced, and suspended in ice-cold isolation
buffer (250 mM sucrose, 10 mM Tris-HCl, 0.5 mM EDTA; pH
7.4), then manually homogenized. The homogenate was
centrifuged for 5 minutes at 1000 × g, and the pellets (nuclear enriched fractions) were frozen prior to DNA isolation. The supernatants were centrifuged for 10 minutes at
12 500×g to obtain enriched mitochondrial pellets, which
were stored at −80°C prior to CcO activity determination.
Mitochondria were subsequently solubilized in 10 mM
potassium phosphate buffer supplemented with 0.2%
n-dodecyl β-d-maltoside (LM) and protease/phosphatase
inhibitors, extracted on ice for 1 hour, and centrifuged at
10 000×g for 10 minutes. Supernatant protein concentration was determined by the Bradford assay.

Enzymatic Activity
The reliability of the CcO and CS activity assays was assessed by estimating precision and accuracy according
to ISO standard 5725-1. Series were compared using
Wilcoxon-rank and Spearman-rank tests. These assays
were performed by the same operator using 2 different
machines.
Spectrophotometric determination of CS (EC 4.1.3.7), a
Krebs cycle enzyme also found in the mitochondria, and
CcO activity levels were performed as previously described.8,14,15 Briefly, CS activity was measured at 415 nm
in potassium phosphate buffer, pH 7.2, with the addition of

Downloaded from https://academic.oup.com/noa/article/4/1/vdab186/6482703 by Washington University, Law School Library user on 16 December 2022

The Cyto-C study was cooperatively developed and implemented by the Network for Excellence in Neuroscience
Clinical Trials (NeuroNEXT), which is sponsored by the
National Institute of Neurological Disorders and Stroke
(NINDS), Grant number U01 NS093663. The trial was designed by a protocol working group and managed by a
protocol steering committee, clinical coordinating center
(CCC), and data coordinating center (DCC) and underwent scientific review and NINDS Council approval.
Cyto-C study is the sixth trial to be conducted by the network and the first in neuro-oncology. Key aspects of this
trial were the prequalification of the clinical sites, centralized ethics oversight, and master clinical trial agreements. Importantly, each site volunteered to participate,
affirmatively stating their interest and ability to enroll and
conduct the trial at their site. The 19 sites participating in
this trial were academic medical centers, which agreed
to participate in a centralized IRB review process prior to
involvement in NeuroNEXT.

Brain tumor tissue was collected in the operating room
of each clinical site during surgery. Approximately 70 mg
of fresh tissue was collected per subject and immediately transferred to sterile ice-cold PBS, then snap-frozen
in liquid nitrogen and labeled with the patient ID number
allocated by the Cyto-C DCC. Clinical sites were provided
with a standard operating procedure (SOP) and 7-min
video describing in detail the procedures for tumor tissue
sample collection, processing samples, and shipping of
the samples. All the individuals involved in tissue collection were required to watch the video and read the SOP,
then sign a Training Log which was sent to the DCC for review and record. A study kit containing the proper items
needed for sample storage and shipment was sent to the
sites in order to assure standardization of the tissue collection process between sites. All evaluable specimens were
snap-frozen within 30 minutes of resection and spent 10
minutes or less at room temperature. Snap-frozen tissue
specimens were immediately stored at −80°C until they
were shipped overnight to the central laboratory for the
Cyto-C study at UAB. After receipt by the central laboratory, tissue specimens were stored at −80°C until they
were processed for CcO and CS activity and MGMT promoter methylation status determination. The detailed SOP
is provided in Supplementary file 2.

Neuro-Oncology
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DNA Isolation
Purified DNA was obtained from the nuclear enriched fraction of each tumor using the QIAamp DNA Kit (Qiagen #
51306) according to the manufacturer’s instructions. The
genomic DNA yields, concentration, and A260/A280 ratio
were determined using a NanoDrop spectrometer based
on the A260 and A280 readings. The genomic DNA integrity
was analyzed on 1% agarose gel.

Methylation-Specific PCR
MGMT promoter methylation patterns were determined
by chemical modification of unmethylated cytosines to
uracil and subsequent PCR using primers specific for either
methylated or unmethylated DNA, according to Esteller
et al.19 DNA was treated with sodium bisulfite as previously
described.20 Briefly, 4 µg of genomic DNA was incubated
with 0.3 M NaOH at 50°C for 20 minutes to denature the
DNA. The mixture was then incubated for 20 hours at 50°C
in 500 µL of a freshly prepared solution containing 3 M sodium bisulfite and 10 mM hydroquinone. DNA was subsequently purified with a Wizard DNA Clean-Up System
(Promega, Madison, WI, USA), following the instructions of
the manufacturer, then resuspended in 100 µL of deionized
H2O and stored at −80°C until use. Primer sequences for
the unmethylated MGMT promoter were: 5′-TTTGTGT
TTTGATGTTTGTAGGTTTTTGT-3′ (forward primer) and
5′-AACTCCACACTCTTCCA AAAACAAAACA-3′ (reverse
primer). Primer sequences for the methylated MGMT promoter were: 5′-TTTCGACGTTCGTAGGTTTTCGC-3′ (forward primer) and 5′-GCACTCTTCCGAAAAC GAAAC G-3′
(reverse primer).19 Optical signals of the methylated and
unmethylated PCR products were quantified with ImageJ
as previously described.21

Statistical Analysis
Study personnel assessing tumor progression were
blinded to the participant’s CcO activity status. As determined in the prior retrospective study, tumors with CcO/
CS ratio scores below or equal to 4 were categorized as
having low CcO activity, while tumors with ratio scores
above 4 were categorized as having high CcO activity. The
full analysis population consisted of all centrally confirmed
eligible participants and was used to address the primary
objective and all analyses looking at OS. A SOC population
was defined as the subset of participants in the full analysis

population for whom death occurred within 12 weeks of
surgery or SOC could be confirmed (any amount of radiation therapy or concomitant TMZ starting within 12 weeks
from the date of surgery or if bevacizumab/avastin was
taken it must have occurred 6 weeks after radiation and/or
concomitant TMZ for patients under 65 and within 3 weeks
for patients 65 and over). The SOC population was used
for all analyses examining PFS as the endpoint. The significance threshold was set at a 2-sided P-value of <.05 for all
analyses.
The primary outcome was OS, defined as the time from
the day of surgery until death from any cause. At the time
of final analysis, the OS of any subject still alive after
24 months from diagnosis was treated as a right-censored
observation. The secondary outcome, PFS, was defined
as the time from the day of surgery for the primary tumor
until tumor recurrence, as detected by clinical and radiographic evidence of progression according to RANO criteria,22 or death from any cause. For patients who were
alive at the time of analysis and did not show progression
at the time of their last routine visit, PFS was treated as a
right-censored observation.
The OS and PFS survival functions were estimated using
the Kaplan-Meier estimator, and the median survival times
and corresponding 95% confidence interval (CI) were reported. Log-rank tests were used to compare survival
between the high vs low CcO tumor activity groups. Cox
proportional hazards regression models were used to estimate the hazard of the OS and PFS events in the high
CcO tumor activity group relative to the low CcO group.
The proportional hazards assumption was assessed by
examining a plot of Schoenfeld residuals against survival
time. The percentage of deaths, which is the percentage of
participants that had an event within a given group of interest during their time on study, was summarized for OS
analyses. A Wilcoxon weighted log-rank test and Fisher’s
exact test comparing the proportion of participants experiencing an event in each group were conducted separately
for OS and PFS as sensitivity analyses. The effect of MGMT
promoter methylation status on OS and PFS was assessed
using similar methods.
The sample size for the primary and secondary objectives was computed based on the log-rank test. We assumed a 2-year event rate of 95% and 30% of participants
displaying high tumor CcO activity levels. For the primary
aim, 145 evaluable subjects provided 95% power to detect
a hazard ratio of 1.85 using a 2-sided log-rank test. Results
of the power analysis indicated the study would be adequately powered to detect clinically meaningful effects for
a reasonable range of anticipated CcO frequencies.
In addition, a multivariate Cox proportional hazards
regression model was used to study the simultaneous
effects of CcO activity level and MGMT promoter methylation status as part of a preplanned exploratory analysis.
The model included main effect terms for both CcO activity
level and MGMT promoter methylation status, as well as
an interaction term to determine if the effect of MGMT
promoter methylation status was moderated by CcO activity level. It was recognized that this approach will provide reasonable power to detect a large interaction, but
a nonsignificant test of interaction cannot be interpreted
to suggest the absence of interaction. Thus, we further
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2.5 mM dithionitrobenzoic acid, 2.5 mM acetyl-CoA, and
10 mM oxaloacetate. The increase in absorbance was used
to calculate CS enzyme activity. CcO activity was measured
in potassium phosphate buffer, pH 7.2, with the addition of
10 µM reduced Cyt c. The oxidation of Cyt c was measured
as the decrease in absorbance at 550 nm and was used to
calculate CcO enzyme activity. CcO activity was expressed
as micromoles of Cyt c oxidized per second per mg protein. The activity of CS remains stable in isolated mitochondria. Therefore, CS activity was used to normalize CcO
activity.16–18
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Study Cohort
The study was registered on ClinicalTrials.gov
(NCT02997423). Central IRB approval for the first site was
obtained on October 31, 2016, with the final site approved
on July 11, 2017. The first subject was enrolled in December
2016, and the last subject was enrolled in June 2020. In all,
259 subjects were consented at an average rate of 0.83 per
site per 30 days. Because subjects were consented before
a final diagnosis of primary GBM, only 152 matched the
eligibility criteria. The main reasons for ineligibility were
(1) subjects not meeting inclusion criteria (81 of 259); (2)
inadequate tissue (40 of 259); (3) GBM not confirmed (36
of 259); and (4) subjects meeting exclusion criteria (34 of
259). Altogether, 104 of the 259 subjects enrolled failed
screening. In addition, 1 patient declined to participate and
2 patients had unevaluated tissue samples that precluded
a central confirmation of eligibility. Among the final study
cohort, approximately half of the subjects were male and
most subjects identified as White (Table 1). Mean age was
61.0 ± 11.1 years.

We first determined the levels of CcO and CS activity in
mitochondria isolated from the primary GBM tissue specimens. CS activity was used to normalize CcO activity in
each sample. The mean CcO/CS ratio for the entire population was 4.40 ± 2.89 (minimum, 0.17; maximum, 15.6;
n = 152). The distribution of CcO/CS activity did not differ
significantly based on demographic and clinical characteristics, including sex; ethnicity; race; height, weight, and age
at surgery; and Karnofsky score (Table 1). We were able to
measure CcO and CS activity in all 152 eligible specimens.
For the entire cohort, median OS was 432 (95% CI, 336
to 502) days, and median PFS was 215 (95% CI, 196 to
264) days (Figure 1A and B). When patients were stratified by tumor CcO activity level (high vs low), neither OS
nor PFS differed significantly between the 2 groups. High
tumor CcO activity was detected in 68 patients (45%) and
low tumor CcO activity was detected in 84 patients (55%).
The median OS was 438 (95% CI, 334 to 496) days among
patients with low tumor CcO activity and 420 (95% CI, 295
to 586) days among patients with high tumor CcO activity
(P = .84 by log-rank test) (Figure 1C). The hazard ratio for
death was 0.96 (95% CI, 0.67 to 1.39). The median PFS
was 211 (95% CI, 177 to 281) days among patients with
low tumor CcO activity and 222 (95% CI, 168 to 297) days
among patients with high tumor CcO activity (P = .85 by
log-rank test) (Figure 1D).

  
Table 1. Study Demographics and Clinical Characteristics
High Tumor CcO Activity (N = 68)

Low Tumor CcO Activity (N = 84)

Total (N = 152)

P-value

Gender
Male

38 (55.9%)

41 (48.8%)

79 (52%)

Female

30 (44.1%)

43 (51.2%)

73 (48%)

.42

Ethnicity
Hispanic or Latino

9 (13.0%)

13 (10.6%)

Non-Hispanic or Latino

50 (92.6%)

4 (7.4%)

60 (87.0%)

110 (89.4%)

Unknown/not reported

14

15

.38

29

Race
White

50 (87.7%)

61 (89.7%)

111 (88.8%)

Non-White

7 (12.3%)

7 (10.3%)

14 (11.2%)

Unknown/not reported

11

16

27

.78

Receipt of SOC
Yes

60 (88.2%)

No

8 (11.8%)

MGMT status-methylateda
Height

(cm)b

78 (92.9%)

138 (90.7%)

6 (7.1%)

14 (9.2%)

.40

11 (19%)

22 (32%)

.15

169 (10.5)

170 (10.5)

.59

Weight (kg)

82 (16.2)

86 (21.8)

.21

Age at surgery

61 (11.6)

61 (10.8)

.85

Karnofsky score

82 (11.4)

82 (9.5)

.85

Abbreviations: CcO, cytochrome C oxidase; SOC, standard of care.
aMGMT status was “undetermined” for 26 participants.
bHeight missing for 1 participant.
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Figure 1. Kaplan-Meier survival curves in patients with newly diagnosed GBM. (A, B) Median OS (A) and median PFS (B) in the full cohort. (C, D)
Median OS (C) and PFS (D) in patients stratified by tumor CcO/CS activity. Low tumor CcO activity (blue line) was defined as CcO/CS ≤ 4 and high
tumor CcO activity (red line) was defined as CcO/CS > 4. Abbreviations: CcO, cytochrome C oxidase; CS, citrate synthase; GBM, glioblastoma; OS,
overall survival; PFS, progression-free survival.
  

OS and PFS by MGMT Promoter
Methylation Status
The secondary objective of the study was to compare
the ability of CcO activity level to prognose OS and PFS
in GBM with the ability of MGMT promoter methylation
status. Tumor MGMT promoter methylation status was undetermined for 26 participants. When patients were stratified by MGMT promoter methylation status (methylated
vs unmethylated), OS and PFS each differed significantly
between the 2 groups. For the OS analysis, MGMT promoter methylation status was determined in the tumors of
126 subjects, of which 33 had methylated promoters and
93 had unmethylated promoters. In the group with methylated promoters, 22 (67%) died, compared to 77 (83%) in the
group with unmethylated promoters. The median OS was
584 (95% CI, 186 to 720) days among patients in the methylated MGMT promoter group, compared with 420 (95% CI,
296 to 464) days among those in the unmethylated MGMT

promoter group (P = .043 by log-rank test) (Figure 2A).
The hazard ratio for death was 0.61 (95% CI, 0.38 to 0.99).
Because the sensitivity analyses were not consistent with
Fisher’s exact test or Wilcoxon weighted log-rank test
(P = .08 and P = .22, respectively), a modified Cox model
was used to allow estimated hazard ratios to differ before
and after 1 year. The hazard ratio for death before 1 year
was 0.88 (95% CI, 0.47 to 1.65), and after 1 year was 0.40
(95% CI, 0.19 to 0.84). For the PFS analysis, MGMT promoter methylation status was established in 114 subjects,
of which 30 had tumors with methylated promoters and
84 had tumors with unmethylated promoters. In the methylated MGMT promoter group, 24 subjects (80%) progressed; in the unmethylated MGMT promoter group, 81
subjects (96%) progressed. The median PFS was 378 (95%
CI, 201 to 635) days among patients in the methylated
MGMT promoter group, compared with 209 (95% CI, 170
to 224) days among those in the unmethylated MGMT promoter group (P < .001 by log-rank test) (Figure 2B).

Downloaded from https://academic.oup.com/noa/article/4/1/vdab186/6482703 by Washington University, Law School Library user on 16 December 2022

0.8

Probability of OS

6

Griguer et al. Prospective biomarker trial in glioblastoma

  

1.0

1.0

+ Censored

Methylated

0.6
Unmethylated

0.4
0.2
0.0

22

21

18

17

16

12

Methylated

0.4
0.2

Unmethylated

100 200 300 400 500 600 700 800
Days from surgery
Participants at risk
Unmethylated 84 70 43 18 12
7
5
3
0

100 200 300 400 500 600 700 800
Days from surgery
Participants at risk
Unmethylated 93 84 67
55 45 29
22
12
0
27

0.6

0.0

0

Methylated 33

0.8

Probability of PFS

Probability of OS

0.8

+ Censored

0

0

Methylated 30

24

21

19

15

12

10

9

0

Figure 2. Kaplan-Meier survival curves in patients with newly diagnosed GBM stratified by tumor MGMT promoter methylation status. (A)
Median OS by MGMT promoter methylation status. (B) Median PFS by MGMT promoter methylation status. Abbreviations: GBM, glioblastoma;
OS, overall survival; PFS, progression-free survival.
  

A

  

High CcO/CS
1.0

B

Low CcO/CS
1.0

+ Censored

0.8

0.6

Probability of OS

Probability of OS

0.8

Unmethylated
MGMT

0.4
Methylated
MGMT

0.2

0

100

200

300

400

Methylated
MGMT

0.6
Unmethylated
MGMT

0.4
0.2

0.0

MGMT

+ Censored

500

600

700

800

Days from surgery
Participants at risk

Unmethylated

46

42

32

25

21

17

13

9

0

Methylated

11

9

6

6

5

4

3

3

0

0.0
300 400 500
Days from surgery
Participants at risk
47
42
35
30
24
12
22
18
16
15
13
13
0

MGMT
Unmethylated
Methylated

100

200

600

700

800

9
13

3
9

0
0

Figure 3. Median survival, log-rank, and Wilcoxon weighted log-rank test for OS by tumor CcO activity and MGMT promoter methylation subgroups. (A) Kaplan-Meier survival function estimate of OS in the high tumor CcO activity group by MGMT promoter status. (B) Kaplan-Meier survival function estimate of OS in the low tumor CcO activity group by MGMT promoter status. Abbreviations: CcO, cytochrome C oxidase; OS, overall
survival.
  

Downloaded from https://academic.oup.com/noa/article/4/1/vdab186/6482703 by Washington University, Law School Library user on 16 December 2022

To explore the association between CcO activity level and
MGMT promoter methylation status, tumors were stratified according to tumor CcO activity level (high or low)
and MGMT promoter methylation status (methylated or
unmethylated) in order to assess whether the effect of methylation status was modified by CcO activity group. Death
occurred in 82% (9/11) in the methylated MGMT promoter/
high CcO activity group, in 78% (36/46) in the unmethylated
MGMT promoter/high CcO activity group, in 59% (13/22) in
the methylated MGMT promoter/low CcO activity group,

and in 87% (41/47) in the unmethylated MGMT promoter/
low CcO activity group. A test of interaction between MGMT
promoter methylation status and CcO activity did not meet
the pre-specified threshold for significance (P = .067).
We further explored post hoc subgroup analyses within
each methylation status group.The hazard ratio of death for
those with methylated vs unmethylated promoter status
within the high CcO activity group was 1.07 (95% CI, 0.51
to 2.22; P = .86). Within the high CcO activity group, the median OS was 351 (95% CI, 97 to 720) days among the methylated MGMT promoters and 336 (95% CI, 239 to 571) days
among the unmethylated MGMT promoters (Figure 3A).
The hazard ratio of death for those with methylated vs
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Discussion
Efficient tumor-specific biomarkers are in high demand,
as they are important in expediting diagnosis at initial
stages, facilitating personalized treatment regimens, and
providing helpful prognostic information for patients and
their families. Despite the challenges faced in transforming
the results of tumor-specific biomarker research into clinical practice, a large number of genomics- and proteomicsderived tumor markers have been proposed as diagnostic,
prognostic, and/or predictive biomarkers of CNS tumors.23
However, numerous challenges have hindered the clinical transformation of preclinical findings regarding these
potential biomarkers. To alleviate such challenges in our
study of CcO activity status as a prognostic biomarker
in GBM, we took advantage of the infrastructure and coordinated experience available through the NeuroNEXT
Network. The Cyto-C study was designed to assess the clinical relevance of CcO activity as a prognostic biomarker
in patients with newly diagnosed GBM. The Cyto-C trial
was designed to ensure that specimens were collected
according to a rigorous protocol, ensuring the documentation of factors that might influence biomarker values or
disease characteristics, and to incorporate specimens from
multiple centers. Cyto-C specimen sets thus have substantial value for use in the discovery phase of other potential
GBM markers.24 The Cyto-C study has many components
of a PRoBE design.25 Indeed, the Cyto-C study is the first
in which biological specimens were collected prospectively from a single cohort of patients with newly diagnosed GBM, which represented the population envisioned
for clinical application of the potential biomarker (ie, tumor
CcO activity and MGMT promoter methylation status).
This design excludes the common sources of bias found in
case-control designs, where specimens are collected after
the disease status is known. Underlining the importance of
such studies, in this prospective biomarker trial, we did not
confirm the prognostic value of CcO activity that was suggested in our previous discovery/retrospective study.14 The
ratio used for this study was chosen based on the optimal
cutoff based on a ROC analysis in that study. To further examine whether this cutoff affected the lack of validation,
a set of exploratory analyses were conducted to evaluate
the findings under alternative cutoff values. An analysis
evaluating cutoff values ranging from 2.0 to 8.0 at 0.5 intervals revealed that the choice of cutoff values did not alter
our final conclusions.
The lack of confirmation in the Cyto-C study may be related to the lack of standardization for tumor tissue collection and storage used in our previous study or the
smaller sample size. In the Cyto-C study, all clinical sites
adhered to the standard operating processes for tumor

tissue collection and storage, allowing uniformity across
all the sites. Other possible reasons for differences in
outcomes in the Cyto-C study (vs our previous study) include the multicenter (vs single center) setting blinded (vs
unblinded) outcomes analysis, pre-stipulated treatment
and follow-up (vs no prospective stipulation of treatment
or follow-up), and direct data collection (vs retrospective
chart review). Another relevant difference may be the statistical design: the Cyto-C study was powered to validate
CcO as a biomarker and both the statistical plan and analysis were developed before doing the assays for CcO activity and MGMT promoter methylation. In contrast, our
retrospective study was not prospectively powered and
the study design was confounded by specimen selection
from a tumor tissue bank, which limited our selection and
information regarding processing and storage protocols. It
is also worth mentioning, while we were unable to validate
CcO activity as a biomarker in the Cyto-C study, the prognostic value of MGMT promoter methylation status was
again demonstrated, validating the overall design, marker
assessment protocol, and data analysis and reporting in
the Cyto-C study. This rigor was due to the coordinated efforts of the CCC, DCC, and the 19 clinical sites enrolling patients in this study.
In addition to suggesting that CcO activity is not a reliable prognostic biomarker in GBM, this study adds value
to the field for several other reasons. First, we report a very
high preoperative consent rate (99.1%). This means that
patients on the cusp of a neurosurgical procedure, under
stress of an unknown diagnosis, are not unapproachable.
On the contrary, the high consent rate suggests they are
very willing to provide excess tissue for research purposes. Second, our results demonstrate that coordination
of multi-institutional biomarker studies in neuro-oncology,
with centralized IRB procedures and requiring rapid tissue
processing is feasible. This study highlights the importance
of having infrastructures such as NeuroNEXT in place to
easily and seamlessly perform prospective biomarker
studies in brain tumors, with centralized analyses that require institution-based standardized processing.
A variety of molecular markers may have prognostic
value in patients with GBM. These markers include high expression of MGMT, overexpression of EGFR, presence of
EGFR vIII mutation, expression of the YKL-40 gene, expression of tenascin-C, PTEN gene mutation or loss of function, loss of chromosome 10, and p53 gene mutation or
loss of function.1,17,26–28 Although MGMT promoter methylation is well established as predicting tumor response
to TMZ and patient outcomes, none of these markers had
been definitively confirmed as a prospective biomarker in
GBM treated with SOC. This trial prospectively confirmed
the prognostic validity of MGMT promoter methylation
status in GBM patients receiving current SOC treatment.2,29
Despite the survival benefit associated with MGMT promoter methylation, the OS curves remained similar for the
first 12 months of follow-up, suggesting that patients with
tumors bearing the methylated MGMT promoter have a
better prognosis 12 months after the initial surgery. TMZ
resistance has been associated with MGMT promoter
methylation in several studies.30–32 However, some studies
have indicated that this correlation does not hold true in
all cases. Thus, Hegi et al1 concluded that there is no clear
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unmethylated promoter status within the low CcO activity
group was 0.43 (95% CI, 0.23 to 0.82; P = .01). The median OS was 634 (95% CI, 203 to undefined) days among
the methylated MGMT promoter/low CcO activity group
compared with 432 (95% CI, 294 to 466) days among the
unmethylated MGMT promoter/low CcO activity group
(P = .004 by log-rank test) (Figure 3B).

Griguer et al. Prospective biomarker trial in glioblastoma

Authorship statement. Clinical design: C.E.G., J.M., C.S.C.,
M.C., D.J.E., L.B.N., and M.C. Conduct of the trial: C.E.G., D.J.E.,
T.M.N.H., M.B., J.R.H., M.C., T.P.L., T.P., H.C., M.F., R.C., K.M.,
N.M., M.G.C., K.M.N., L.B.N., P.K., A.D., J.D., S.K., A.K., T.B., E.G.,
C.O., and J.M. Analysis: C.E.G., C.O., C.S.C., A.L.G., D.J.E., and
J.K.F. Writing of manuscript: C.E.G., C.O., J.M., L.B.N., C.S.C.,
R.A.C., M.G.C., and R.C. Approval of final manuscript: all authors.

Supplementary Material
Supplementary material is available at Neuro-Oncology
Advances online.

References
Keywords
biomarker | cytochrome C oxidase | glioblastoma | MGMT |
prospective clinical trial

1.

2.

Funding
This study was supported by the National Institute of
Neurological Disorders and Stroke (NINDS), National Institutes
of Health [grant No. U01 NS093663].

3.

4.

Acknowledgments

5.

We wish to acknowledge NINDS and the NeuroNEXT consortium for their administrative support and scientific contributions. We appreciate the contribution of NeuroNEXT site
principal investigators, the scientists at the Data Coordinator

6.

Hegi ME, Liu L, Herman JG, et al. Correlation of O6-methylguanine
methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol. 2008;26(25):4189–4199.
Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing
and benefit from temozolomide in glioblastoma. N Engl J Med.
2005;352(10):997–1003.
Poon MTC, Sudlow CLM, Figueroa JD, Brennan PM. Longer-term
(≥2 years) survival in patients with glioblastoma in population-based
studies pre- and post-2005: a systematic review and meta-analysis. Sci
Rep. 2020;10(1):11622.
Schafer N, Gielen GH, Rauschenbach L, et al. Longitudinal heterogeneity
in glioblastoma: moving targets in recurrent versus primary tumors. J
Transl Med. 2019;17(1):96.
Becker AP, Sells BE, Haque SJ, Chakravarti A. Tumor heterogeneity in
glioblastomas: from light microscopy to molecular pathology. Cancers
(Basel). 2021;13(4):761–783.
Szopa W, Burley TA, Kramer-Marek G, Kaspera W. Diagnostic and therapeutic biomarkers in glioblastoma: current status and future perspectives. Biomed Res Int. 2017;2017:8013575.

Downloaded from https://academic.oup.com/noa/article/4/1/vdab186/6482703 by Washington University, Law School Library user on 16 December 2022

Conflict of interest statement. L.B.N. is a member of the
Scientific Advisory Board of Karyopharma and Data Safety and
Monitoring Board of UPENN; M.F. is a Board Member of Agios
Pharmaceuticals and Forma Therapeutics.

Neuro-Oncology
Advances

Center (University of Iowa) and Clinical Coordinator Center
(Mass General Hospital), and Dr. Robert O’Donnell (University
of California Davis). We are especially grateful to the
NN106 clinical coordinators: Barbara Terwilliger (Columbia
University), Angela Molloy (University of Cincinnati), Jason
Gorup (University of Kansas), Brittany Bent (MGH), Julie
Steele (University of Miami), Justine Houseman (Northwestern
University), Amy Bartlett (Ohio State University), Kellie
Keith (Oregon Health and Science), Melinda Vargas-Jaffe
(University of Pittsburgh), Jennifer Serventi (University of
Rochester), Jessica Lamb (SUNY Stony Brook), Nathan
Hansen (Swedish Medical Center), Erica Goude (University
of California Davis), William Thayer (UTSW), Amy Magalanes
(University of Utah), Sally Furukawa (Vanderbilt University),
and Mengesha Teshome (Washington University). Lastly, Dr.
Erin Thacker for manuscript editing.

relationship between MGMT promoter methylation and a
favorable response to TMZ treatment. These contradictory
findings indicate the need to combine MGMT promoter
methylation status with other biomarkers.33 Over the past
decades, it has been clear that while MGMT methylation
status has gained center stage, its specificity and selectivity performances are poor. Using CcO status upstream of
MGMT methylation status could increase the performance
of MGMT as a “true predictive marker” and significantly
decrease the number of false-positive and false-negative
cases and thus improve medical decisions and treatment
strategy. We are beginning to understand a novel mechanism by which CcO drives resistance to TMZ/radiation.
DNA damage and repair can be affected by cell metabolism in that the regulation of ROS through different metabolic pathways can increase oxidative damage to DNA.7,34
Epigenetic silencing of the MGMT gene by methylation of
the promoter region has been shown to correlate with loss
of expression of the MGMT protein resulting in decreased
DNA repair.2 High levels of ROS in tumors harboring low
CcO activity impose an extra burden for DNA repair.7 Low
CcO activity (high ROS) and MGMT promoter methylation
(lower DNA repair) may possibly explain why patients in
this cohort had better outcomes following TMZ/radiation
treatment. The results of this trial show that the combination of low CcO activity and MGMT promoter methylation
may identify patients with GBM who are likely to be longterm survivors of SOC. Although tumor CcO activity alone
was not confirmed as a prognostic marker in patients
GBM, the interaction between CcO and methylated MGMT
promoter warrants further evaluation.
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